SLC30A8: A Potential Drug Target and Biomarker (G169026)

Target Name: SLC30A8

NCBI ID: G169026

SLC30A8

SLC30A8: A Potential Drug Target and Biomarker

Sodium-glucose cotransporter 30 (SLC30A8) is a gene that encodes a protein known as the Na+-glucose cotransporter. This protein plays a crucial role in the regulation of the body's blood sugar levels and is expressed in the endothelium, which is the lining of the blood vessels. SLC30A8 has been identified as a potential drug target and biomarker for several diseases, including diabetes, heart failure, and cancer.

SLC30A8 is a transmembrane protein that is expressed in the endothelium and is responsible for the reabsorption of sodium and glucose into the bloodstream. This protein has been shown to play a role in the regulation of blood sugar levels and has been linked to several diseases. For example, SLC30A8 has been shown to be expressed in the endothelium of diabetic rats and is involved in the regulation of glucose uptake and storage.

SLC30A8 has also been shown to be involved in the regulation of heart failure. This protein has been shown to be expressed in the endothelium of heart failure patients and is involved in the regulation of sodium and glucose uptake and storage in the heart. This may contribute to the development of heart failure as a result of high levels of sodium and glucose in the body.

In addition to its role in the regulation of blood sugar and heart failure, SLC30A8 has also been shown to be involved in the regulation of cancer cell growth. This protein has been shown to be expressed in the endothelium of cancer cells and is involved in the regulation of sodium and glucose uptake and storage. This may contribute to the development and progression of cancer.

SLC30A8 is also a potential biomarker for several diseases, including diabetes, heart failure, and cancer. This protein can be used as a diagnostic marker for these diseases and may also be used as a target for new drugs. For example, inhibitors of SLC30A8 have been shown to be effective in treating diabetes and heart failure. Additionally, SLC30A8 has also been shown to be involved in the regulation of cancer cell growth and may be a potential target for cancer therapies.

In conclusion, SLC30A8 is a gene that encodes a protein that plays a crucial role in the regulation of blood sugar and heart failure. This protein has been shown to be involved in the regulation of sodium and glucose uptake and storage in the endothelium and has been linked to several diseases, including diabetes, heart failure, and cancer. As a potential drug target and biomarker, SLC30A8 may be a valuable tool for the development of new treatments for these diseases.

Protein Name: Solute Carrier Family 30 Member 8

Functions: Proton-coupled zinc ion antiporter mediating the entry of zinc into the lumen of pancreatic beta cell secretory granules, thereby regulating insulin secretion

The "SLC30A8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC30A8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets